三生制药(01530)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01530 三生制药

交易中 09-08 13:57:40

16.450

+0.410

+2.56%

最高16.630	最低15.870	成交量1,069万
今开16.200	昨收16.040	日振幅4.74%
总市值415.86亿	流通市值415.86亿	总股本25.28亿
成交额1.74亿	换手率0.42%	流通股本25.28亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01530","market":"HK","secType":"STK","nameCN":"三生制药","latestPrice":16.45,"timestamp":1788847041923,"preClose":16.04,"halted":0,"volume":10691469,"delay":0,"changeRate":0.025561097256857866,"floatShares":2528000000,"shares":2528000000,"eps":4.008022502744238,"marketStatus":"交易中","change":0.41,"latestTime":"09-08 13:57:40","open":16.2,"high":16.63,"low":15.87,"amount":173676878,"amplitude":0.047382,"askPrice":16.45,"askSize":81000,"bidPrice":16.44,"bidSize":45000,"shortable":3,"etf":0,"ttmEps":3.796528620283833,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1788855000000},"marketStatusCode":2,"adr":0,"listingDate":1433952000000,"exchange":"SEHK","adjPreClose":16.04,"dividendRate":0.015204,"openAndCloseTimeList":[[1788831000000,1788840000000],[1788843600000,1788854400000]],"volumeRatio":1.0372,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"SBI.HK","impliedVol":0.5186,"impliedVolPercentile":0.3333},"requestUrl":"/m/hq/s/01530/wiki","defaultTab":"wiki","newsList":[{"id":"1101822470","title":"三生制药：娄竞增持，好仓比例升至21.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=1101822470","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101822470?lang=zh_cn&edition=full","pubTime":"2026-09-07 17:32","pubTimestamp":1788773538,"startTime":"0","endTime":"0","summary":"娄竞于2026年9月7日以每股均价16.0港元买入三生制药股份49.00万股，涉资约784.00万港元。娄竞此次增持前持有三生制药好仓5.34亿股，占比21.11%；增持后持股量为5.34亿股，好仓比例升至21.13%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f7700173111443e192ac74957e46cb69","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665398249","title":"【券商聚焦】中信建投：上半年收入与利润双增，医药行业步入新发展周期","url":"https://stock-news.laohu8.com/highlight/detail?id=2665398249","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665398249?lang=zh_cn&edition=full","pubTime":"2026-09-07 09:04","pubTimestamp":1788743053,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指，2026年上半年医药行业整体收入与扣非净利润实现双增长，创新药、CXO、制药装备及科学试剂等板块积极复苏，行业步入新发展周期。创新药收入+58.68%，扭亏为盈，出海总金额超900亿美元，全年有望超越2025年水平，国际化持续兑现；CXO收入+25.2%，扣非净利润+66.5%，订单旺盛，上行周期确立。随着集采出清、创新放量、出海落地及上游国产化提升，行业有望开启高质量发展周期，龙头将持续受益。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1990791","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01789","02367","BK1585","LU2488822045.USD","LU1720050803.USD","BK1191","02228","KURE","LU0228659784.USD","LU0417516902.SGD","BK1161","LU2778985437.USD","BK1500","KCE","06821","BK1141","BK1593","601066","01099","09688","06160","IE00B5MMRT66.SGD","SG9999004311.SGD","LU2476274308.USD","IE00B3M56506.USD","LU0828237510.HKD","LU1770034418.SGD","LU2476274720.SGD","BK1197","LU0348825331.USD","01530","LU2399975544.HKD","02268","BK1207","BK1100","HK0000165453.HKD","BK1588","02196","BK1574","LU1969619763.USD","03933","09926","LU0348827113.USD","LU2328871848.SGD","LU0640798160.USD","BK1515","LU1115378108.SGD","BK1583","IE00BPRC5H50.USD","LU0588546209.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664238859","title":"【券商聚焦】交银国际：医药行业收入稳健增长 多重利好推动盈利表现显著改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2664238859","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664238859?lang=zh_cn&edition=full","pubTime":"2026-09-04 09:00","pubTimestamp":1788483634,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际表示，1H26港股/A股医药行业整体收入增长4.7%/3.2%。创新药产业链增速领跑行业，服务板块复苏：1）港股/A股CXO收入整体增长29.2%/25.3%，（扣非）净利润增长23.4%/67.6%，在各子板块中增速最快，行业整体景气度和订单需求处于高位。2）核心成药板块收入增长17.8%/3.4%、利润增长62.7%/35.0%。其中生物药增速远超化药，在板块收入中的占比也进一步提升。3）医院、器械、诊断、疫苗等板块业绩有复苏趋势。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1990646","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177","09996","BK1515","01548","LU1152091168.USD","02269","LU0348783233.USD","LU0588546209.SGD","LU0856984785.SGD","HK0000320264.USD","LU1242518857.USD","01801","09926","02162","06160","02096","LU1251922891.USD","LU0039217434.USD","03692","00013","06078","BK1589","03759","09966","06821","IE00B0JY6N72.USD","01530","02596","LU0307460666.USD","KURE","IE00B543WZ88.USD","BK1209","LU2543165471.USD","LU0315179316.USD","LU0327786744.USD","01951","02273","IE00B5MMRT66.SGD","01952","01093","BK1161","KCE","03329","SG9999004220.SGD","01276","06996","LU1880383366.USD","06990","HK0000306685.HKD","02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664870226","title":"【生物医药小白投研】第八篇：小白完整投研框架与体系复盘","url":"https://stock-news.laohu8.com/highlight/detail?id=2664870226","media":"港股解码","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664870226?lang=zh_cn&edition=full","pubTime":"2026-09-03 16:10","pubTimestamp":1788423000,"startTime":"0","endTime":"0","summary":"经过前七篇的认知、排雷、管线、赛道、BD、估值、交易节奏全维度学习，本篇作为专栏终章，复盘整套投研体系，整合核心知识点，帮助新手建立系统化的投资决策习惯。对仅有纸面高额交易额、低首付、小公司噱头BD的标的保持警惕。作者丨吴言编辑丨Jasmine往期推荐:第七篇：看得懂基本面，更要把握交易节奏第六篇：小白也能上手的医药股估值与前景打分体系第五篇：读懂BD的价值逻辑第四篇：分清黄金赛道与内卷红海","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzI2MDAzMTQ4OA==&mid=2650514079&idx=1&sn=b343b5c979b09868c5b4b6ffa6bf3616&chksm=f3613873bcb2e49ac858ccd3d88ca34c5f10e2143037b5c049e758da1d990257cd4b54d9d0b6&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["BK1583","LU0572944931.SGD","LU0828237510.HKD","LU1969619763.USD","06160","LU0516423174.USD","BK1500","LU0029874061.USD","LU0856984785.SGD","LU2242644610.SGD","SG9999004220.SGD","LU1794554557.SGD","LU2488822045.USD","LU0455707207.USD","BK1588","03692","LU0880133367.SGD","LU1188198961.HKD","LU0181495838.USD","LU0348735423.USD","LU1328277881.USD","LU2039709279.SGD","LU0359201612.USD","01530","01093","LU1880383366.USD","LU0456846285.SGD","KURE","LU0320764599.SGD","LU0244354667.USD","02269","HK0000165453.HKD","LU1720050803.USD","IE00B0JY6N72.USD","LU0359202008.SGD","LU1251922891.USD","IE00BZ08YT58.USD","01801","LU1960683339.HKD","LU1813983027.USD","LU0067412154.USD","BK1589","LU2097828631.EUR","BK1515","LU0128526141.USD","LU1807302812.USD","LU1008478684.HKD","LU2097828474.EUR","LU0072913022.USD","LU0051755006.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176098747","title":"三生制药9月2日回购150万股股份，涉资约2,358.50万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1176098747","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176098747?lang=zh_cn&edition=full","pubTime":"2026-09-02 19:31","pubTimestamp":1788348707,"startTime":"0","endTime":"0","summary":"三生制药(01530)于2026年9月2日公告，公司在香港联交所场内回购普通股合计150万股，占当日回购前公司已发行股本0.06%，每股回购价格介乎港币15.70元至15.75元，合计涉资约2,358.50万港元。回购完成后，公司已发行股本减少至2,528,243,912股，库藏股数量增至10,020,500股。\n根据公告，购回授权于2026年6月25日获得通过，公司可回购的总股份数为253,707,141股。截至目前，已累计回购9,007,500股，余下可回购股份数为244,699,641股。公司确认此次回购过程符合香港联交所证券上市规则及相关法规要求。\n本公告由公司秘书黎少娟签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"三生制药9月2日回购150万股股份，涉资约2,358.50万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664181643","title":"三生制药(01530)9月2日斥资2358.5万港元回购150万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2664181643","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664181643?lang=zh_cn&edition=full","pubTime":"2026-09-02 19:29","pubTimestamp":1788348580,"startTime":"0","endTime":"0","summary":"智通财经APP讯，三生制药(01530)发布公告，于2026年9月2日斥资2358.5万港元回购150万股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491146.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","HK0000165453.HKD","BK1161","01530","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100725998","title":"三生制药更新8月股份变动月报表，股本小幅增加","url":"https://stock-news.laohu8.com/highlight/detail?id=1100725998","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100725998?lang=zh_cn&edition=full","pubTime":"2026-09-02 16:37","pubTimestamp":1788338235,"startTime":"0","endTime":"0","summary":"三生制药于2026年9月2日发布截至2026年8月31日止的股份变动月报。公告显示，公司法定注册股本维持在50,000,000,000股普通股，每股面值0.00001美元，注册股本金500,000美元，与上月保持一致。公告未披露任何购回或注销股份事项。当月股份变动主要来自2015年5月23日采纳并于2016年6月28日修订的股份期权计划。期间共有25,000股期权被行使，行使价每股7.62港元，合计筹资190,500港元。本次月报由公司秘书黎少娟签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663944021","title":"里昂：降三生制药(01530)目标价至30.4港元 维持“跑赢大市”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2663944021","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663944021?lang=zh_cn&edition=full","pubTime":"2026-08-31 11:40","pubTimestamp":1788147600,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，里昂发布研报称，三生制药(01530)上半年业绩受惠于707里程碑收入及CDMO业务强劲增长，抵销了核心产品销售疲弱的影响。虽然近期收入增长仍然低迷，但新一轮产品上市周期及707全球开发项目的进一步进展，应能支持中期增长。该行维持予其“跑赢大市”评级，目标价由32.6港元下调至30.4港元。该股现持有逾186亿元人民币现金，撇除现金后，现交易于预测未来一年市盈率7.4倍。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1489266.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159431755","title":"异动解读｜三生制药盘中下跌5.07%，辉瑞BD折价配股落地叠加板块整体承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1159431755","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159431755?lang=zh_cn&edition=full","pubTime":"2026-08-31 10:24","pubTimestamp":1788143043,"startTime":"0","endTime":"0","summary":"8月31日，三生制药盘中下跌5.07%，报16.1港元，成交额1.78亿港元。消息面上，三生制药与辉瑞的重大BD交易正式落地，公司以折价约17%向辉瑞配售新股，市场担忧短期股权稀释压力。此前辉瑞以超60亿美元引进三生制药PD-1/VEGF双抗SSGJ-707，正在全球推进多项三期临床。同时，公司上半年归母净利润同比下滑15.6%至11.47亿元，传统产品销售收入同比下降19.3%，内生业务承压已被多家券商确认。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"辉瑞折价配股落地，三生制药承压走低","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662094216","title":"【生物医药小白投研】第五篇：读懂BD的价值逻辑","url":"https://stock-news.laohu8.com/highlight/detail?id=2662094216","media":"港股解码","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662094216?lang=zh_cn&edition=full","pubTime":"2026-08-28 16:50","pubTimestamp":1787907000,"startTime":"0","endTime":"0","summary":"在生物医药二级市场，BD是出现频率最高、对股价影响较为直接的核心词汇之一。但在A股、港股创新药赛道，能够对股价形成重大催化的BD交易，大多特指药物全球权益授权交易。首付款是海外顶级药企对药物当下真实价值的投票，是BD含金量的核心判断依据。BD出海让一款药物同时覆盖国内+全球市场，估值逻辑彻底升级。例如科伦博泰、信达生物等，持续兑现出海BD，研发实力全球认可。NO.6小白必须警惕以下BD误区误区一：BD落地股价必涨。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzI2MDAzMTQ4OA==&mid=2650514013&idx=2&sn=a94c778f97f0744682cc347b39421f20&chksm=f382c39a6e71d39b1967e69c7fe65ec399f4658e5a18b93c3b2c95e183487c32d8cdc7dd65d9&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["LU1969619763.USD","01801","BK1589","LU2488822045.USD","BK1500","BK1593","LU2097828474.EUR","LU0502904849.HKD","LU0326950275.SGD","06160","LU0228659784.USD","LU1770034418.SGD","BK1583","688235","LU2097828805.USD","LU2097828714.EUR","LU0307460666.USD","LU2242644610.SGD","BK1161","LU0196878994.USD","LU2097828631.EUR","LU1303224171.USD","LU2328871848.SGD","01530","LU1188198961.HKD","LU2097828557.USD","KURE","LU1719994722.HKD","06990","LU1251922891.USD","ONC","LU0244354667.USD","LU0828237510.HKD","LU0463099449.HKD","HK0000165453.HKD","LU0588546209.SGD","BK1588","LU0455707207.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662760675","title":"【券商聚焦】国信证券维持三生制药（01530）优于大市评级 指707有望成重磅炸弹","url":"https://stock-news.laohu8.com/highlight/detail?id=2662760675","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662760675?lang=zh_cn&edition=full","pubTime":"2026-08-26 14:01","pubTimestamp":1787724066,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国信证券发布研报指，三生制药 2026年上半年实现营收45.26亿元人民币，毛利率为83.8%，其中产品销售收入34.43亿元、授权收入8.52亿元、CDMO业务收入2.31亿元；归母净利润11.47亿元，经调整的经营性归母净利润14.36亿元。CDMO基地沈阳德生已为辉瑞提供临床药品原液，未来将持续供货。707快速开启全球3期多中心临床，有望成为重磅炸弹，维持“优于大市”评级。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/MTU3MGM5Y2M3ZDk5Mjg2ODIwNjM2NDU0OA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MTU3MGM5Y2M3ZDk5Mjg2ODIwNjM2NDU0OA==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1989481","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["002736","KCE","01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661223843","title":"【券商聚焦】招银国际维持三生制药（01530）“买入”评级 707的全球临床推进仍是主要上行催化","url":"https://stock-news.laohu8.com/highlight/detail?id=2661223843","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661223843?lang=zh_cn&edition=full","pubTime":"2026-08-24 13:22","pubTimestamp":1787548948,"startTime":"0","endTime":"0","summary":"金吾财讯 | 招银国际研报指，三生制药 1H26实现营收45.3亿元，主要得益于707里程碑收入贡献；剔除授权收入后的常规业务收入36.7亿元，反映增值税调整、医保控费及VBP带来的压力。该机构认为市场已对2026年产品销售端的短期压力有所预期，而707的全球重磅潜力仍是主导上行因素。该机构下调近期产品销售预测以反映传统产品持续承压，但鉴于辉瑞全球临床开发的快速推进，上调2026E里程碑收入预测。","market":"nz","thumbnail":"https://static.szfiu.com/news/20241108/YzM1MzBiNWM5MmUxNDYxMGFiODk0MWI5MWJmNTU3YjMxMTA4MTkwNzI1ODY3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YzM1MzBiNWM5MmUxNDYxMGFiODk0MWI5MWJmNTU3YjMxMTA4MTkwNzI1ODY3.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1989178","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KCE","01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661324037","title":"中金：维持三生制药(01530)跑赢行业评级 下调目标价至30.00港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2661324037","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661324037?lang=zh_cn&edition=full","pubTime":"2026-08-24 10:59","pubTimestamp":1787540377,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，考虑内生业务压力，下调三生制药26/27净利润6%/12%至28.42亿元/30.51亿元。维持跑赢行业评级，考虑板块估值中枢略有下移,该行下调目标价18%至30.00港元对应23.1倍/20.9倍26/27年市盈率，隐含68%上行空间。中金主要观点如下：1H26业绩符合市场预期公司公布1H26业绩：营业收入45.26亿元，同比增长3.9%;归母净利润11.47亿元，同比下滑15.6%，经调整归母净利润14.36亿元，同比增长26.5%。1H26公司实现CDMO收入2.31亿元，该行预计主要是向辉瑞提供SSGJ-707原液带动。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1484014.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01530","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661251291","title":"港股午评|恒生指数早盘涨0.72%     锂矿股涨幅居前","url":"https://stock-news.laohu8.com/highlight/detail?id=2661251291","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661251291?lang=zh_cn&edition=full","pubTime":"2026-08-21 12:00","pubTimestamp":1787284830,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，港股恒生指数涨0.72%，涨184点；恒生科技指数指数涨0.50%；港股早盘成交1360亿港元。天齐锂业涨8.8%；赣锋锂业涨超7%。恒生指数公司将于今日公布第二季度指数评估结果。思格新能或加入港股通标的，涨超10%。恒基地产涨超6%领涨蓝筹。中期股东应占盈利40.9亿港元，同比增加40.65%。中软国际绩后涨超7%，上半年股东应占溢利3.5亿元，同比增加11%。金嗓子盈警后跌超21%，预计上半年纯利同比跌四成，受销售费用增加拖累。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1483113.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["07500","HK0000252152.HKD","HK0000500386.USD","LU1166156734.SGD","BK1518","HHImain","LU0880133367.SGD","BK1601","HK0000914660.USD","03067","SG9999003461.SGD","LU1008478684.HKD","03033","LU0359201612.USD","LU1152091754.HKD","BK1610","02706","LU1224709979.USD","LU0173614495.USD","BK1586","BK1190","BK1589","LU1808992512.USD","01378","03419","BK1161","HK0000165453.HKD","BK1592","LU1303224171.USD","03423","03032","07226","LU0287142896.SGD","07300","HSTECH","LU0067412154.USD","LU0345780950.USD","HK0001040168.HKD","LU0345781412.USD","LU2279858448.HKD","03088","09088","02833","HK0000286598.CNH","BK1594","BK1113","BK1526","82800","06896","06869","601869","LU0307460666.USD","BK1559","LU0588546209.SGD","00354","LU1770034418.SGD","LU1251922891.USD","09696","01866","02600","HK0000914686.HKD","09067","LU0264606111.USD","09115","BK1117","HK0000252160.HKD","LU1960683339.HKD","BK1509","LU0051755006.USD","03037","002460","LU0572940350.SGD","LU0737861699.HKD","LU0359202008.SGD","BK1207","01772","BK1116","00012","BK1543","LU0572939691.SGD","LU0630314457.HKD","BK1506","BK1513","LU0210526637.USD","03417","LU1171460220.USD","601600","BK1240","06656","BK1522","MCHmain","BK1593","02800","BK1175","83115","BK1155","SG9999014674.SGD","BK1511","00189","BK1583","SG9999006597.SGD","LU0456827905.SGD","LU1152091168.USD","BK1523","03115","LU0702159699.USD","01530","BK1149","BK1568","03750","LU1719994722.HKD","HSI","LU1023057109.AUD","LU1807302812.USD","07552","HLDCY","BK1500","07200","002466","SG9999001093.SGD","513600","BK1170","LU0469268626.HKD","02788","LU1993786604.SGD","BK1129","HK0001040143.USD","LU0359201885.HKD","300750","02837"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106720631","title":"异动解读｜三生制药盘中上涨5.58%，中期业绩发布叠加新药获批提振情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1106720631","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1106720631?lang=zh_cn&edition=full","pubTime":"2026-08-21 09:46","pubTimestamp":1787276780,"startTime":"0","endTime":"0","summary":"8月21日，三生制药盘中上涨5.58%，报17.47港元，成交额1.95亿港元。消息面上，公司于8月20日发布中期业绩，上半年实现营业收入45.26亿元，同比增长3.9%；归母净利润11.47亿元，同比下降15.6%，但经调整经营性归母净利润14.4亿元，同比增长26.5%。海外产品销售同比增长43%，核心品种获全球23个国家上市许可。此外，国家药监局于8月20日正式批准公司旗下非甾体抗炎药物的上市申请，进一步增强公司在抗炎镇痛领域的竞争力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"三生制药盘中上涨，新药获批叠加业绩催化","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660233703","title":"三生制药发布2026中期业绩：创新驱动、合作共赢、行稳致远","url":"https://stock-news.laohu8.com/highlight/detail?id=2660233703","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660233703?lang=zh_cn&edition=full","pubTime":"2026-08-20 23:17","pubTimestamp":1787239022,"startTime":"0","endTime":"0","summary":"三生制药今日发布2026年中期业绩公告。今年上半年，公司实现营业收入45.3亿元，同比增长3.9%，归母净利润11.5亿元，经调整的经营性归母净利润14.4亿元，同比增长26.5%，研发费用6.8亿元，同比增长24.9%，公司财务资源194亿元，充裕的资金储备为研发投入和战略布局提供了坚实保障。上半年核心品种获全球23个国家上市许可，海外产品销售同比增长43%，来源于公司rhEPO、益赛普、rhTPO等品种在全球多个新兴经济体国家提升市场渗透率。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260820/32341912.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1161","BK1583","01530","HK0000165453.HKD","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660238133","title":"三生制药(01530.HK)发布中期业绩，股东应占溢利11.47亿元 同比减少15.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660238133","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660238133?lang=zh_cn&edition=full","pubTime":"2026-08-20 22:33","pubTimestamp":1787236399,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1593","BK1583","01530","HK0000165453.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176184899","title":"三生制药(01530)发布中期业绩：2026年上半年收入45.26亿元、净利11.47亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1176184899","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176184899?lang=zh_cn&edition=full","pubTime":"2026-08-20 22:32","pubTimestamp":1787236370,"startTime":"0","endTime":"0","summary":"2026年8月20日，三生制药披露截至2026年6月30日止六个月未经审计的中期业绩。收入45.26亿元，同比增长3.9%，增幅为1.71亿元；毛利37.95亿元，同比增长2.1%，毛利率由85.3%降至83.8%；归属股东净利润11.47亿元，同比减少2.12亿元，降幅15.6%；基本每股收益0.45元，较上年同期的0.57元下降21.1%。生物药品销售收入34.43亿元，同比下降19.3%；截至报告期末，现金及现金等价物、无抵押定期存款及已抵押存款合计124.69亿元；报告期内，客户A贡献收入9.93亿元；","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153271973","title":"国家药监局批准三生制药非甾体抗炎药上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1153271973","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153271973?lang=zh_cn&edition=full","pubTime":"2026-08-20 09:59","pubTimestamp":1787191149,"startTime":"0","endTime":"0","summary":"国家药品监督管理局正式批准了三生制药旗下非甾体抗炎药物的上市申请。这一决定标志着该药物在完成严格的临床研究与审评流程后，获得了进入中国市场的通行证。值得注意的是，非甾体抗炎药作为临床常用的镇痛消炎类药物，其市场潜力与治疗价值备受关注。业内人士指出，该药物的获批将进一步增强三生制药在抗炎镇痛领域的竞争力。三生制药方面表示，将持续致力于高质量药物的研发与生产，以满足未被满足的医疗需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530","BK1161","HK0000165453.HKD","BK1593","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156392389","title":"异动解读｜三生制药盘中上涨5.15%，中报发布日叠加生物科技板块走强","url":"https://stock-news.laohu8.com/highlight/detail?id=1156392389","media":"行情直击","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156392389?lang=zh_cn&edition=full","pubTime":"2026-08-20 09:31","pubTimestamp":1787189477,"startTime":"0","endTime":"0","summary":"8月20日，三生制药盘中上涨5.15%，报17.55港元，成交额545.19万港元。消息面上，公司董事会于今日召开会议审议并批准刊发截至6月30日止六个月的未经审核中期业绩，并考虑派发中期股息。市场对中报业绩存在积极预期，此前有机构指出公司坐拥特比澳等多个现金牛品种，高毛利率水平下盈利弹性值得关注。同日生物科技板块整体走强，云顶新耀涨49.24%，康方生物涨6.33%，信达生物涨5.24%，科伦博泰生物涨4.01%，百济神州涨3.85%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"三生制药盘中上涨5.15%，中报发布日叠加生物科技板块走强","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.3sbio.com","stockEarnings":[{"period":"1week","weight":-0.005},{"period":"1month","weight":-0.1074},{"period":"3month","weight":0.0562},{"period":"6month","weight":-0.2568},{"period":"1year","weight":-0.5436},{"period":"ytd","weight":-0.3268}],"compareEarnings":[{"period":"1week","weight":-0.006},{"period":"1month","weight":-0.0099},{"period":"3month","weight":0.0345},{"period":"6month","weight":-0.0188},{"period":"1year","weight":-0.0002},{"period":"ytd","weight":-0.0085}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"3SBio Inc是一家主要从事生物制药产品的开发、生产、市场推广及销售的投资控股公司。该公司的主要产品包括特比澳、益比奥、益赛普、赛普汀等生物药物以及蔓迪、丽美治等小分子药物。该公司还从事为客户提供多种生物药的研发生产以及治疗技术平台服务的合同开发与生产运营（CDMO）业务。该公司的产品主要应用于血小板减少症（CIT）、慢性肾病（CKD）引起的贫血症、治疗化疗引起的贫血症（CIA）、强直性嵴柱炎（AS）及银屑病等。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":-0.006634},{"month":2,"riseRate":0.454545,"avgChangeRate":0.001777},{"month":3,"riseRate":0.818182,"avgChangeRate":0.113184},{"month":4,"riseRate":0.454545,"avgChangeRate":-0.011081},{"month":5,"riseRate":0.636364,"avgChangeRate":0.080953},{"month":6,"riseRate":0.727273,"avgChangeRate":0.025359},{"month":7,"riseRate":0.166667,"avgChangeRate":-0.034677},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.015863},{"month":9,"riseRate":0.583333,"avgChangeRate":0.024774},{"month":10,"riseRate":0.454545,"avgChangeRate":-0.018318},{"month":11,"riseRate":0.727273,"avgChangeRate":0.059928},{"month":12,"riseRate":0.454545,"avgChangeRate":-0.045348}],"exchange":"SEHK","name":"三生制药","nameEN":"3SBIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"三生制药(01530)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供三生制药(01530)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"三生制药,01530,三生制药股票,三生制药股票老虎,三生制药股票老虎国际,三生制药行情,三生制药股票行情,三生制药股价,三生制药股市,三生制药股票价格,三生制药股票交易,三生制药股票购买,三生制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"三生制药(01530)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供三生制药(01530)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}